InspireMD, Inc. 8-K
Research Summary
AI-generated summary
InspireMD Announces 30‑Day Clinical Results for CGuard Prime 80 cm
What Happened On June 11, 2026, InspireMD, Inc. announced 30‑day results from the CGUARDIANS II clinical trial for its CGuard Prime 80 cm implant intended for use in TCAR (transcarotid artery revascularization) procedures. The company furnished a press release as Exhibit 99.1 to a Form 8‑K under Item 7.01 (Regulation FD Disclosure).
Key Details
- Announcement date: June 11, 2026.
- Trial: CGUARDIANS II — 30‑day results reported for CGuard Prime 80 cm implant.
- SEC filing: Form 8‑K (Item 7.01); press release furnished as Exhibit 99.1.
- Exhibit listing also included the Inline XBRL cover page (Exhibit 104) in the filing.
Why It Matters Clinical trial updates are material to investors because they provide progress signals on product performance, potential regulatory milestones, and future commercial prospects. This 30‑day update is an official public disclosure (Regulation FD) and may be relevant to assessing InspireMD’s development timeline and risk profile; investors should review the furnished press release (Exhibit 99.1) for the detailed results and any forward steps the company outlines.
Loading document...